CHRS Q1 2026 Earnings Call Transcript
Chimerix (NASDAQ: CHRS) reported $11.8 million in Loqtorzi net sales for Q1 2026, a 61% year-over-year increase but lower than the previous quarter due to seasonality and winter storm impacts. The company set new patient start records with increased ordering accounts and treatment duration. Management expects average quarterly demand growth of 10%-15% in 2026 for Loqtorzi.
